Bladder Cancer: Risk Factors, Emerging Treatment Strategies and Challenges

Samantha Haggerty (Editor)

Series: Cancer Etiology, Diagnosis and Treatments
BISAC: MED062000

Clear

$192.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

Bladder cancer is the fifth most common form of cancer worldwide and is mainly prevalent in developed countries. It is thought to arise through two distinct pathways: the noninvasive and the invasive. The noninvasive pathway gives rise to a superficial papillary carcinoma that is characterized by activating mutations in oncogenes such as H-ras, FGFR3 and PI3K.

This pathway is rarely lethal as superficial papillary carcinomas can be readily removed through transurethral resection. However, 15% of noninvasive urothelial tumors can transform into invasive carcinomas and have high recurrence (80% of the cases) that requires intensive surveillance and repetitive treatment. This book discusses the risk factors of bladder cancer, as well as the emerging treatment strategies and challenges. (Imprint: Nova Biomedical )

Preface

Chapter 1 - Cancer Stem Cell (CSC) in Bladder Malignancy (pp. 1-16)
Jianmin Zhang, Maxime Blijlevens and Nuo Yang (Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY, USA, and others)

Chapter 2 - The Five Senses in Bladder Cancer Diagnostics (pp. 17-44)
Caterina Gulia, Giacinto Marrocco, Santiago Vallasciani and Roberto Piergentili (Dipartimento di Scienze Ginecologico-Ostetriche e Scienze Urologiche, Policlinico Umberto I, Sapienza - Università di Roma, Italy, and others)

Chapter 3 - Bladder Cancer in Pediatric Patients (pp. 45-70)
Santiago Vallasciani, Giacinto Marrocco, Caterina Gulia, Andrea Zangari and Roberto Piergentili (UOSD di Urologia Pediatrica, Policlinico Maggiore, Milano, Italy, and others)

Chapter 4 - Multi-Tasking Chemoinformatic Model for the Efficient Discovery of Potent and Safer Anti-Bladder Cancer Agents (pp. 71-94)
Alejandro Speck-Planche and M. N. D. S. Cordeiro (REQUIMTE/Department of Chemistry and Biochemistry, University of Porto, Porto, Portugal)

Chapter 5 - Long Non Coding Mitochondrial RNAs As Potential Targets for Diagnosis and Therapy of Bladder Cancer (pp. 95-116)
Jaime Villegas, Alexis Rivas, Rodolfo Ávila, Vincenzo Borgna, Lorena Lobos-Gonzales Verónica Burzio, Constanza López, Reynaldo Gomez, Eduardo Landerer, Laura Velarde and L. O. Burzio (Andes Biotechnologies S.A., Fundación Ciencia & Vida, Chile, and others)

Chapter 6 - Histological Variants of Urothelial Carcinoma: Diagnostic, Prognostic and Therapeutic Implications (pp. 117-144)
Hyung Suk Kim and Ja Hyeon Ku (Department of Urology, Seoul National University College of Medicine)

Chapter 7 - Novel Therapeutic Modalities in Patients with Advanced or Metastatic Urothelial Carcinoma (pp. 145-160)
Kazumasa Matsumoto, Masaomi Ikeda, Takahiro Hirayama, Tetsuo Fujita and Masatsugu Iwamura (Department of Urology, Kitasato University School of Medicine)

Index

You have not viewed any product yet.


SHOW ALL OF MY RECENTLY VIEWED BOOKS